Risvutatug  (Synonyms: HS-20093 Antibody; GSK5764227 Antibody)

HS-20093 Antibody (GSK5764227 Antibody) is an antibody targeting B7-H3, which can be used to synthesize the ADC HS-20093. HS-20093 Antibody exhibits anti-tumor activity. HS-20093 Antibody can be studied in research for small cell lung cancer, relapsed or refractory osteosarcoma, and advanced solid tumors^[1][2][3].

Human IgG1 kappa

Human IgG1 kappa, Isotype Control

Human

ADC antibodies act as the navigation system of ADC drugs and are primarily responsible for delivering payloads to target cells.

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

80381  [NCBI]

Q5ZPR3

ELISA, FACS, Functional assay

Unconjugated

The product can be reconstituted/diluted with sterile PBS or saline.

143.94 kDa

3042848-87-0

Liquid

Colorless to light yellow

[Risvutatug]

Shipping with dry ice.

Please refer to the lot-specific COA for specific buffer information.

Please store the product under the recommended conditions in the Certificate of Analysis.

• 
  IgG1-lambda

• 
  Immobilized huB7H3-His can bind Risvutatug. The EC₅₀ for this effect is 13.41 ng/mL.

• [1]. J. Wang, et al., OA04.06 Efficacy and Safety of HS-20093 in Extensive Stage Small Cell Lung Cancer in A Multicenter, Phase 1 Study (ARTEMIS-001). Volume 19, Issue 10, Supplement S17, 2024

  [2]. Lu Xie, et al., ARTEMIS-002: Phase 2 study of HS-20093 in patients with relapsed or refractory osteosarcoma. Journal of Clinical Oncology. 42(16), 2024

  [3]. Jie Wang, et al., ARTEMIS-001: Phase 1 study of HS-20093, a B7-H3–targeting antibody-drug conjugate, in patients with advanced solid tumor. Journal of Clinical Oncology. 41 (16), 2023.